| Literature DB >> 34903981 |
Leyla Karadurmus1,2, Goksu Ozcelikay1, Sena Vural1, Sibel A Ozkan1.
Abstract
Quantum dots (QDs) are one of the first nanotechnological materials to be integrated with sensor technologies and have been widely anticipated to eventually find application chances in several commercial pharmaceutical and clinical products. They are one of the most important developments in the rapidly growing world of material science technology. The excellent properties of QDs may allow the design of simple, precise, and inexpensive electrochemical methods for the detection of pharmaceuticals. Electrochemical techniques offer accuracy, high sensitivity, low cost, simplicity, ease of preparation of the samples in a very short time, and speed of analysis. The most commonly used voltammetric techniques are differential pulse voltammetry, cyclic voltammetry, square wave voltammetry, and stripping voltammetry. The purpose of this review is to show and communicate the advantages and uses of QD applications used in drug analysis. Besides, the present application methods of QDs to the pharmaceutical analysis and their related parameters were summarized between 2012 and 2021 years and summarized as a table.Entities:
Keywords: Drug analysis; Electroanalytical methods; Quantum dots; Voltammetry
Year: 2021 PMID: 34903981 PMCID: PMC8653673 DOI: 10.22037/ijpr.2021.115279.15291
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1Statistics of the number of publications per year related to quantum dot-based nanocomposites for electrochemical sensing
Selected quantum dots based electrochemical studies for different active compounds
| Active Compound | Method | Transducer | Linear Range | LOD/LOQ | Application | Reference |
|---|---|---|---|---|---|---|
| Catecholamine | CV | GQD/Lac/GCE | 1–120 μM | 83 nM /126 nM | Pharmaceutical samples | ( |
| Curcumin | DPV | CQD/GCE | 0.4-200 μM | 0.1 μM | Turmeric powder | ( |
| Metanil yellow | 0.06- 50 μM | 0.03 μM | ||||
| Metobromuron | DPV | MIP/Au NPs@NCDS @Ag NPs/GCE | 1 pM–2 nM | 0.2 pM | Wastewater samples | (40) |
| Oxalic acid | Amperometric | NH2-GQD/GO/GCE | 0.5-2 mM | 50 μM | Urine samples | ( |
| Metronidazole | DPV | CuCo2O4/N-CNTs/MIP/GCE | 0.005–0.1 μM | 0.48 nM | Pharmaceutical samples Human serum sample | ( |
| Caffeic acid | DPV | N-CQD/HP-Cu2O/MWCNT/GCE | 0.05–43 μM | 0.004 μM | Red wine sample | ( |
| Quercetin | DPV | NH2- GQD/Au-β-CD/GCE | 1-210 nM | 285 pM | Honey | ( |
| Sofosbuvir | DPV | MIP/AuNPs/ N,S@GQD/PGE | 1–400 nM | 0.36 nM | Human serum sample Pharmaceutical samples | ( |
| Vitamin B2 | DPV | PGBHA-NH2-GQD/MnO2 NCs/GCE | 0.1 to 100 μM | 0.04 μM | Real sample | ( |
| Dopamine | 0.05 μM | |||||
| Flutamide | DPV | N-CQD@Co3O4/ | 0.05-590 μM | 0.0169 μM | Human urine sample | ( |
| Nitrofurantoin | 0.05-1220 μM | 0.044 μM | ||||
| Oxaliplatin | DPV | CQDs@HBNNS/UiO-66-NH2 /MIP/GCE | 1-250 nM | 0.37 nM | Human serum sample | ( |
| Daunorubicin | DPV | CQD/PGE | 0.1 -0.5 μM | 37 nM | 5 mM phosphate buffer solution | ( |
| Dopamine | DPV | MIP/Au/N-GOQDs/NiS2/BC/GCE | 0.05–40.0 µM | 0.0028 | Pharmaceutical samples Human serum sample | ( |
| Chlorpromazine | 0.005–2.0 µM | 0.00025 | ||||
| Dobutamine | DPV | N-GQDs/NiMnO3/CPE | 0.08–40.0 μM | 0.02 μM | Human serum sample | ( |
| p-aminophenol | CV | CdS/CPE | 100-1400μM | 2 μM/ | - | ( |
| Cocaine | DPV | AgNPs-Apt/CdTe QDs/GCE | 0.05–6000 nM | 0.005 nM | Human serum sample | ( |
| Doxorubicin hydrochloride | DPV | GQD/GCE | 0.018–3.60 μM | 0.016μM | Human serum sample | ( |
| Hydroxylated polychlorobiphenyls | SWV | Tyr-ZnO QDs/GO/GCE | 2.8–27.65μM | 0.15 μM | Phosphate buffer solution | ( |
| Methyldopa | DPV | TGA-CdSe@Ag2Se QDs/GCE | 0.09- 60 μM | 0.04 μM | Pharmaceutical samples | ( |
| Olanzapine | CV | BMBPBP/CdS-QDs/MWCNTs/Au electrode | 0.02–100μM | 0.006μM | Pharmaceutical samples Human serum sample | ( |
| Clopidogrel | AdSDPV | fMWCNT/CdSe QDs/GCE | 2–40 μM | 0.076 μM | phosphate buffer solution | ( |
| Lamivudine | DPV/ | Ni-CoS/ GQDs/GCE | - | 56.18 μg/mL / 56.13 μg/mL | 0.1 M phosphate buffer solution (pH 8) | ( |
| Dopamine | DPV | GQD/SPE | 0.1–1000 μM | 0.05 μM | Pharmaceutical samples | ( |
| Acetaminophen | DPV | GQD/GCE | 5–80 μM | Pharmaceutical samples | ( | |
| L-DOPA | DPV | Fe3O4@GODs/ fMWCNTs/GCE | 3-400 μM | 14.3 nM | Sunflower seed, | ( |
| Doxorubicin | DPV | GQD-GCE | 0.018–3.6 μM | 0.016 μM | Human serum sample | ( |
| Cholesterol | DPV | β-CD@N-GQD/GCE | 0.5–100 μM | 0.08 μM | Human serum sample | ( |
| Vitamin C | CV | Fe3O4@GQDs/GCE | 0.1-9 μM | - | 0.1 M pH 7.4 PBS | ( |
| Nitrite | SWV | MWCNT-Chit/CdTe QD-CTAB/GCE | 1–100 μM | 0.30 μM | Pickled vegetable | ( |
| Levofloxacin | DPV | PoAP/GQD/GCE | 0.05 to 100 μM | 10 nM | Milk samples | ( |
| Lidocaine | DPV | Cd1-xMgxTe/QD-GO/CPE | 5.08 – 14.4 μM | 1.1 μM | Human urine sample | ( |
| Cd1-xMgxTe/QD-rGO/CPE | 2.55 -14.4 μM | 95 nM | ||||
| Epinephrine | Cd1-xMgxTe/QD-GO/CPE | 0.43-1.49 μM | 0.41 nM | |||
| Cd1-xMgxTe/QD-rGO/CPE | 0.109- 1.49 μM | 9.2 nM | ||||
| Folic acid | CV | nSe@ZnS/electrode | 12-96 nM | 0 nM | Pharmaceutical samples | ( |
| Acetaminophen | DPV | GA@O-CQDs/GCE | 0.001–10 μM | 0.38 nM | Pharmaceutical samples | ( |
| Clozapine | DPV/CV | NiO/GQD/GCE | 3.0–1000 nM | 0.55 nM | Human serum sample | ( |
| Nevirapine | DPV | Pd@rGO/ MoS2 QDs GCE | 0.1–80 μM | 0.05 μM | Human serum solution | ( |
| Doxorubicin hydrochloride | DPV | GQDs/Poly (TA/β-CD) /Au electrode | 0.086 μM to | 0.012 μM | Human serum solution | ( |
| Rilpivirine | DPV | CQD/MWCNT/AgNPs/GCE | 1-7 nM | 0.03 nM | Human serum samples | ( |
| Irinotecan | DPV/CV | GQDs-PANI/ZnO/ GCE | 0.1 - 25.μM | 0.011 μM | Aqueous Solution | ( |
| 5-Fluorouracil | 0.1 – 50 μM | 0.023 μM | ||||
| Donepezil HCl | CV | SBT/ N-CNDs/ CoNPs /PGE | 1.5 nM-400 μM | 0.5 nM | Pharmaceutical samples | ( |
| Zolpidem | DPV | GQDs/DMCCE | 0.1–1 μM | 0.061μM | Pharmaceutical samples | ( |
| Norfloxacin | SWAdASV | CdTe QDs/CB/ Chit/EPH/GCE | 0.2-7.4 μM | 6.6 nM | Pharmaceutical samples | ( |
| Sotalol | DPV | MIP/AuNPs/GQD/ | 0.1–250 μM | 0.035 μM | Pharmaceutical samples | ( |
| Chloroquine | CV | rGO@WS2/GCE | 0.5 - 82 μM | 0.04 μM | Pharmaceutical samples | ( |
| DPV | 0.5 - 82 μM | 0.04 μM | ||||
| Uric acid | DPV, CV | CdSeQD/HF-PGE | 0.297-2.970 mM | 0.0833 μM | Pharmaceutical samples Human serum sample | ( |
| Creatinine | 0.442-8.840 mM | 0.229 μM | ||||
| 6-Mercaptopurine | DPV | MIP/sol-gel/ZnO@GQDs/PGE | 0.01-50.0 μM | 5.72nM | Pharmaceutical samples Human serum sample | ( |
| Kaempferol | SWV | PVP/CdS QDs/CPE | 0.06-2 μM | 0.06 μM | Pharmaceutical samples | ( |
| Metronidazole | DPV | GQDs-MIPs/GNPs/GCE | 0.005–0.75 μM | 0.52 nM | Human serum sample | ( |
| Vitamin C | SWV | GQD/β-CD/GCE | 0.01–170 μM | 0.49 μM | Human serum sample | ( |
| Dopamine | SWV | QDMCPE | 75 nM–0.6 μM | 21 nM | Pharmaceutical samples Human serum sample | ( |
| Uric Acid | 7.5 μM –1.4 mM | |||||
| Dextromethorphan | DPV | PDDA/MWCNT/CQD/PGE | 2-600 μM | 0.19 μM | Pharmaceutical samples Human serum sample | ( |
| Malachite green | DPV | (GQDs/AuNp)n/GCE | 0.4 - 10 μM | 0.1 μM | Fish samples | ( |
| L-tyrosine | DPV | β-CD/GQD/GCE | 0.1 -1.5 μM | 100 nM | - | ( |
| Acetaminophen | DPV | Fe3O4@SiO2-PDDA-CNT/GCE | 10-110 μM | 39 nM | - | ( |
| Isoproterenol | DPV | GQDs/SPE | 1.0 - 900.0 μM | 0.6 μM | Human urine sample | ( |
| Methyldopa | SWV | GQDs-IL/CPE | 0.04-750 μM | 0.01 μM | Pharmaceutical samples Human serum sample | ( |
| Theophylline | DPV | GQD/SPE | 1.0– 700.0 μM | 0.2 μM | Theophylline oral solution | ( |
| Topotecan | DPV | ds-DNA /GQD/IL/CPE | 0.35–100.0 μM | 0.1 μM | Human serum sample | ( |
| Imidacloprid | DPV | GQDs/IL/MWCNT/PANI/GCE | 0.03 -12.0 μM | 9 nM | Vegetable samples | ( |
| Dopamine | DPV | Au-GQDs-Nafion/GCE | 2 - 50 μM | 0.84 μM. | Human urine sample | ( |
| Tyrosinamide | EIS | N-acetyl-l-cysteine-capped Ag-In-S QDs/GCE | 0.01 to 2.81 nM and 2.81–10.81 | 3.34 pM | Human serum sample | ( |
| Bisphenol S | DPV | CQD/ AgNP /MIP/GCE | 10 nM-0.05 mM | 11.2 nM | Plastic products | ( |
| Pimozide | DPV | NH2-fMWCNT/ decorated with and ZnONPs/ GQD/GCE | 0.0625-120nM | 0.0102 nM | Pharmaceutical samples Human serum sample | ( |
| Uric acid | DC-AMP | CQD/ Fe3O4/GCE | 0.01-0.145 μM | 6 nM | Human urine sample | ( |
| Diethylstilbestrol | LSV | GQD/SPCE | 0.05 -7.5 μM | 8.8 nM | Human urine sample | ( |
| Paracetamol | DPV | PS-PNIPAm-PS / COOHfMWCNT-GQDs / GCE | 0.1-7.0 μM | 66 nM | Human serum sample Pharmaceutical samples | ( |
| Hydroquinone | DPV | CuO-His-GQD/GCE | 0.001–40 μM | 0.31 nM | Natural water samples | ( |
| Dopamine | LSV | CQDs/GCE | 0.19 – 11.81 μM | 2.7 μM | - | ( |
| Uric acid | 0.21 – 13.39 μM | 1.3 μM | ||||
| Amoxicillin | SWV | QDs-P6LC-PEDOT:PSS/GCE | 0.90–69.0 μM | 0.05 μM | Milk sample | ( |
| Bisphenol S | DPV | hNiNS/GQDs/MIPs/GCE | 0.1–50 μM | 0.03 μM | Plastic samples | ( |
| Epinephrine | SWV | GQD-CS/CPE | 0.36–380.0 μM | 0.0003 μM | Human serum sample | ( |
| Arginine | DPV | fMWCNT/CdSe/HF-PGE | 0.287–33670 μM | 0.081 μM | Real samples | ( |
| Alanine | ||||||
| Methionine | ||||||
| Cysteine | ||||||
| Amino acids | ||||||
| Riboflavin | DPV | N-CQD/SnO2/SPE | 0.05–306 μM | 8 nM | B complex tablet | ( |
| Cisplatin | DPASV | GQDs-thio/npGCE | 0.2-110 μM | 0.09 μM | Human serum sample | ( |
| Vitamin C | DPV | PPy-BPQDs-MIPs/PEDOTNRs/GCE | 0.01–4 mM | 0.0033 mM | Soft drink : | ( |
| Calycosin | DPV | PAGD/GCE | 11 μM -0.352 mM | 9.8 μM | Astragali Radix | ( |
| Dopamine | DPV | GQDs/GCE | 0.4- 100 | 0.05 μM | Real Sample | ( |
| Hydroquinone | DPV | GQDs/GCE | 0.5-100 μM | 0.08 | River water samples | ( |
| Dexamethasone | DPV | GNP/GCE | 0.1–50 μM and 50–5000 μM | 15 nM | Human serum sample | ( |
| Amitriptyline | DPV | MagNPs/CQD/GCE | 0.05–13.50 μM | 0.0059 μM | Uric acid, | ( |
| Melatonin | 0.0044 μM | |||||
| Tryptophan | 0.0042 μM | |||||
| Ciprofloxacin | DPV | LDH/CdTe QD/CPE | 25 nM- 12 μM | 42 nM | Zn2+, Fe2+, Cu2+, | ( |
| Norepinephrine | SWAdASV | GQD/AuNP/GCE | 0.5–7.5 μM | 0.15 μM | Pharmaceutical samples | ( |
| Dopamine | DPV | SnO2/N-GQD/PANI/GCE | 0.5–200 μM | 0.22 μM | L-ascorbic acid | ( |
| Hydrazine | CV | CdSe @ NiHCF NPs/electrode | 1.6–1000 μM | 0.5 μM | Tap water | ( |
| Ascorbic acid | DPASV | GO/CdTe QDs/GCE | 32.3–500.0 μM | 6.1 μM | Fruit juice | ( |
| Acetaminophen | DPV | GA@O-CQDs/GCE | 0.001–10 μM | 0.38 nM | Pharmaceutical samples | ( |
| Carbendazim | DPV | ZnCdTe QD-rGO/CPE | 99.8 nM -11.8 μM | 91.6 nM | Orange juice | ( |
| L- Tryptophan | DPV | NH2-GQDs/β-CD/GCE | 1.0–30.0 μM | 0.65 μM | 10 mM Phosphate buffer | ( |
| D-Tryptophan | 0.12 μM | |||||
| L-cysteine | DPV | AgNPs/GQDs/GCE | 0.2mM-10 μM | 10 nM | - | ( |
| Phenylethanolamine A | CV | MIP/C3N4NTs@GQDs/Ru@AuNPs/GCE | 1 pM-1 nM | 0.2 pM | Human urine sample | ( |
| Uric acid | CV | UOx/GQDs/GCE | 1–800 μM | 0.3 μM | Human serum sample | ( |
| Ascorbic acid | DPV | rGO/CdSeQD/GCE | 0.39–1.0 mM | 66 μM | Human urine sample | ( |
| Dopamine | 4.9-74 μM | 0.11 μM | ||||
| Uric acid | 9.0 μM –0.12mM | 0.12 μM | ||||
| Estradiol | DPV | GQDs/ PSSA/GCE | 0.001–6.0 μM | 0.23 nM | Human serum sample | ( |
| Progesterone | 0.31 nM | |||||
| Alprazolam | DPV | Ag/N-GQD/Au electrode | 56–156 | 56 | Human serum sample | ( |
| Diazepam | 54–142 | 54 | ||||
| Clonazepam | 84-625 | 84 | ||||
| Oxazepam | 54–454 | 54 | ||||
| Chlordiazepoxide | 52–250 | 52 |
Figure 2Disadvantages and advantages of quantum dots in an electrochemical sensor